Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Assets: 2019-2025

Historic Current Assets for Silence Therapeutics (SLN) over the last 7 years, with Sep 2025 value amounting to $133.6 million.

  • Silence Therapeutics' Current Assets fell 34.70% to $133.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $639.3 million, marking a year-over-year decrease of 27.38%. This contributed to the annual value of $187.4 million for FY2024, which is 81.64% up from last year.
  • As of Q3 2025, Silence Therapeutics' Current Assets stood at $133.6 million, which was down 10.04% from $148.6 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Current Assets ranged from a high of $230.5 million in Q1 2024 and a low of -$13.3 million during Q3 2021.
  • Moreover, its 3-year median value for Current Assets was $148.6 million (2025), whereas its average is $156.0 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 1,107.62% in 2022, then crashed by 34.70% in 2025.
  • MRQ analysis of 5 years shows Silence Therapeutics' Current Assets stood at $116.4 million in 2021, then fell by 2.55% to $113.4 million in 2022, then dropped by 9.04% to $103.2 million in 2023, then skyrocketed by 81.64% to $187.4 million in 2024, then fell by 28.68% to $133.6 million in 2025.
  • Its Current Assets was $133.6 million in Q3 2025, compared to $148.6 million in Q2 2025 and $169.8 million in Q1 2025.